Dianthus Therapeutics Inc (DNTH)

Currency in USD
20.39
-0.85(-4.00%)
Closed·
After Hours
21.60+1.21(+5.93%)
·
DNTH Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual Post-Market activity
DNTH is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
19.8021.63
52 wk Range
13.3732.27
Key Statistics
Prev. Close
21.24
Open
21.16
Day's Range
19.8-21.63
52 wk Range
13.37-32.27
Volume
377.29K
Average Volume (3m)
321.6K
1-Year Change
-27.77%
Book Value / Share
10.23
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DNTH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
51.78
Upside
+153.94%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings downwards for the upcoming period

Dianthus Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Dianthus Therapeutics Inc Company Profile

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company’s lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Compare DNTH to Peers and Sector

Metrics to compare
DNTH
Peers
Sector
Relationship
P/E Ratio
−6.5x−1.8x−0.5x
PEG Ratio
−0.19−0.070.00
Price/Book
2.0x2.8x2.6x
Price / LTM Sales
100.5x66.2x3.3x
Upside (Analyst Target)
135.4%303.2%43.5%
Fair Value Upside
Unlock10.6%6.9%Unlock

Analyst Ratings

13 Buy
0 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 51.78
(+153.94% Upside)

Earnings

Latest Release
May 12, 2025
EPS / Forecast
-0.82 / -0.50
Revenue / Forecast
1.16M / --
EPS Revisions
Last 90 days

DNTH Income Statement

People Also Watch

8.68
PHAT
+3.58%
13.17
STOK
+1.62%
14.41
KROS
+0.14%
174.39
ALAB
+28.66%
136.00
KRYS
-0.98%

FAQ

What Stock Exchange Does Dianthus Therapeutics Trade On?

Dianthus Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Dianthus Therapeutics?

The stock symbol for Dianthus Therapeutics is "DNTH."

What Is the Dianthus Therapeutics Market Cap?

As of today, Dianthus Therapeutics market cap is 655.74M.

What Is Dianthus Therapeutics's Earnings Per Share (TTM)?

The Dianthus Therapeutics EPS (TTM) is -2.81.

From a Technical Analysis Perspective, Is DNTH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Dianthus Therapeutics Stock Split?

Dianthus Therapeutics has split 1 times.

How Many Employees Does Dianthus Therapeutics Have?

Dianthus Therapeutics has 78 employees.

What is the current trading status of Dianthus Therapeutics (DNTH)?

As of 07 Aug 2025, Dianthus Therapeutics (DNTH) is trading at a price of 20.39, with a previous close of 21.24. The stock has fluctuated within a day range of 19.80 to 21.63, while its 52-week range spans from 13.37 to 32.27.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.